These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 39172542)

  • 1. GIP receptor antagonism eliminates paradoxical growth hormone secretion in some patients with acromegaly.
    Jensen MH; Gasbjerg LS; Skov-Jeppesen K; Jacobsen JCB; Poulsen SS; Zhou C; Jakubauskaite R; Poulsen FR; Bonde C; Albarazi M; Halle B; Christiansen CB; Sanni SJ; Byberg S; Hoe B; Holst JJ; Dela F; Rasmussen AK; Knop FK; Arlien-Søborg MC; Melmed S; Jørgensen JOL; Andersen MS; Hartmann B; Klose MC; Feldt-Rasmussen U; Sparre-Ulrich AH; Rosenkilde MM
    J Clin Endocrinol Metab; 2024 Aug; ():. PubMed ID: 39172542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of
    Regazzo D; Losa M; Albiger NM; Terreni MR; Vazza G; Ceccato F; Emanuelli E; Denaro L; Scaroni C; Occhi G
    Eur J Endocrinol; 2017 May; 176(5):543-553. PubMed ID: 28179449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly.
    Umahara M; Okada S; Ohshima K; Mori M
    Endocr J; 2003 Oct; 50(5):643-50. PubMed ID: 14614222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells.
    Occhi G; Losa M; Albiger N; Trivellin G; Regazzo D; Scanarini M; Monteserin-Garcia JL; Fröhlich B; Ferasin S; Terreni MR; Fassina A; Vitiello L; Stalla G; Mantero F; Scaroni C
    J Neuroendocrinol; 2011 Jul; 23(7):641-9. PubMed ID: 21554434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas.
    Chasseloup F; Regazzo D; Tosca L; Proust A; Kuhn E; Hage M; Jublanc C; Mokhtari K; Dalle Nogare M; Avallone S; Ceccato F; Tachdjian G; Salenave S; Young J; Gaillard S; Parker F; Boch AL; Chanson P; Bouligand J; Occhi G; Kamenický P
    Eur J Endocrinol; 2024 Feb; 190(2):173-181. PubMed ID: 38330165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose.
    Hage M; Janot C; Salenave S; Chanson P; Kamenický P
    Eur J Endocrinol; 2021 May; 184(6):R261-R268. PubMed ID: 33830942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor.
    Oba-Yamamoto C; Kameda H; Miyoshi H; Sekizaki T; Takase T; Yanagimachi T; Fujita Y; Nomoto H; Cho KY; Nakamura A; Nagai S; Atsumi T
    Intern Med; 2021; 60(15):2375-2383. PubMed ID: 34334589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylator Phenotype and Ectopic GIP Receptor in GNAS Mutation-Negative Somatotropinomas.
    Hage M; Chaligné R; Viengchareun S; Villa C; Salenave S; Bouligand J; Letouzé E; Tosca L; Rouquette A; Tachdjian G; Parker F; Lombès M; Lacroix A; Gaillard S; Chanson P; Kamenický P
    J Clin Endocrinol Metab; 2019 May; 104(5):1777-1787. PubMed ID: 30376114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.
    Regazzo D; Barbot M; Scaroni C; Albiger N; Occhi G
    Rev Endocr Metab Disord; 2020 Mar; 21(1):165-183. PubMed ID: 31933128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH
    Gasbjerg LS; Hartmann B; Christensen MB; Lanng AR; Vilsbøll T; Jørgensen NR; Holst JJ; Rosenkilde MM; Knop FK
    Bone; 2020 Jan; 130():115079. PubMed ID: 31622777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.
    Gasbjerg LS; Gabe MBN; Hartmann B; Christensen MB; Knop FK; Holst JJ; Rosenkilde MM
    Peptides; 2018 Feb; 100():173-181. PubMed ID: 29412817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
    De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
    Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Methylation Analysis of the
    Dalle Nogare M; D'Annunzio S; Vazza G; Regazzo D; Picello L; Denaro L; Voltan G; Scaroni C; Ceccato F; Occhi G
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Preoperative Paradoxical GH Response to Oral Glucose Load Predicts a low Risk of Recurrence in Acromegaly.
    Losa M; Garbin E; Calcagnile R; Voltan G; Ceccato F; Scaroni C; Occhi G; Mortini P
    J Clin Endocrinol Metab; 2024 Jun; ():. PubMed ID: 38878276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive expertise in endocrinology: glucose-dependent insulinotropic peptide-dependent Cushing's syndrome.
    Lacroix A
    Eur J Endocrinol; 2023 Mar; 188(3):R56-R72. PubMed ID: 36857084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor.
    Ravn P; Madhurantakam C; Kunze S; Matthews E; Priest C; O'Brien S; Collinson A; Papworth M; Fritsch-Fredin M; Jermutus L; Benthem L; Gruetter M; Jackson RH
    J Biol Chem; 2013 Jul; 288(27):19760-72. PubMed ID: 23689510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
    Garcia EA; Trivellin G; Aflorei ED; Powell M; Grieve J; Alusi G; Pobereskin L; Shariati B; Cudlip S; Roncaroli F; Mendoza N; Grossman AB; Harper EA; Korbonits M
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1918-26. PubMed ID: 24152687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly.
    Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G
    J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly.
    Giustina A; Bresciani E; Bussi AR; Bollati A; Bonfanti C; Bugari G; Chiesa L; Giustina G
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1333-40. PubMed ID: 7536207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.